Aspirin for Secondary Prevention of Atherosclerosis—Evidence or Dogma?

Authors

John G.F. Cleland (ORCID: https://orcid.org/0000-0002-1471-7016)

Institutions

British Heart Foundation (GB)
University of Glasgow (GB)

Publication Details

Journal: JAMA Cardiology
Published: 2024-12-04
DOI: https://doi.org/10.1001/jamacardio.2024.4335
Citations: 8
Primary Topic: Antiplatelet Therapy and Cardiovascular Diseases
Type: article
Field-Weighted Citation Impact: 3.22

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Aspirin for Secondary Prevention of Atherosclerosis—Evidence or Dogma?

John G.F. Cleland

Dec 4, 2024

8 citations

JAMA Cardiology

Antiplatelet Therapy and Cardiovascular Diseases

3.22

article

Aspirin for Secondary Prevention of Atherosclerosis—Evidence or Dogma?

John G.F. Cleland

December 4, 2024article en

8 citations

Abstract

No abstract available for this paper.

JAMA CardiologyVol. 10(2)

British Heart Foundation (GB), University of Glasgow (GB)

Openalex Percentile: Top 7%

Antiplatelet Therapy and Cardiovascular Diseases

3.22

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Aspirin for Secondary Prevention of Atherosclerosis—Evidence or Dogma? — John G.F. Cleland · JAMA Cardiology (2024) | TGRS Research Map | TGRS